March 10th 2022
2022 Presenting Companies
Achilles Therapeutics (GB)
Achilles Therapeutics is a biopharmaceutical company developing novel cancer immunotherapies targeting clonal neoantigens: protein markers unique to each individual that are expressed on the surface of every cancer cell. Achilles uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. Targeting multiple clonal neoantigens that are present on all cancer cells, but not on healthy cells, allows individualised treatments to target and destroy tumours without harming healthy tissues.
Aelin Therapeutics (BE)
Aelin Therapeutics secured a 27 M€ Series A investment to exploit its proprietary Pept-in™ protein knockdown platform as a novel modality in drug development. Company will exploit its proprietary platform technology to develop a new class of antibiotics and first-in-class therapeutics against high-value undruggable human targets in oncology. The Peptin technology harnesses the power of protein aggregation to specifically induce functional knockdown of a target protein. The technology allows for the rational design of novel biotherapeutics and differentiates itself from any other therapeutic modality through its unique mode of action, its designability and intracellular target space out of reach for other therapeutics.
AgomAB Therapeutics (BE)
AgomAb is translating a deep expertise in growth factor biology to pioneer and develop novel treatments to repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases. The team has raised around $100M from top US and EU investors.
AM-Pharma is a clinical stage biopharmaceutical company, leading in the development of a treatment for AKI with its innovative recombinant human Alkaline Phosphatase therapeutic (recAP). AKI is a devastating disease with high mortality rate that affects millions of patients worldwide. There is no approved pharmacological treatment for AKI and our biologic, recAP, has the potential to be a life-saving first-in-class medicine.
Amolyt Pharma (FR)
Amolyt Pharma, a clinical stage biotechnology company, is building on its team’s established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Its portfolio includes AZP-3601, a long-acting PTH analog as a potential treatment of hypoparathyroidism, AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly, and AZP-3404, which is undergoing indication selection work. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors. To learn more, visit https://amolytpharma.com/
Atlantic Therapeutics (IE)
We are Atlantic Therapeutics, an Irish developer of professional and consumer medical devices, related software and connected health technologies.
At Atlantic Therapeutics, our focus is on the treatment of incontinence, sexual health dysfunctions and other associated disorders, and are on a mission to help the millions of people suffering globally by strengthening the muscles and modulating the nerves of the pelvic floor.
We develop and manufacture medical device-quality pelvic floor strengthening and nerve stimulation products — all backed by strong clinical evidence and subjected to controlled trials. Healthcare professionals across the world rely on Atlantic Therapeutics to improve thousands of lives every year. All Atlantic Therapeutics Group Ltd. products are certified under the European Medical Devices Directive 93/42/EEC.
With 1 in 3 women and 1 in 10 men experiencing urinary incontinence to some degree every single day, estimating that around 400 million people globally are suffering, we have a huge opportunity to transform lives every day by helping to restore their bladder control and confidence.
Aviado Bio (GB)
AT AVIADOBIO WE ARE GUIDED BY OUR HEARTS AND MINDS
Our purpose is to transform the lives of patients living with some of the most debilitating and life-threatening neurodegenerative disorders such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) through the potential of gene therapy.
We are building on pioneering research from King’s College London and the UK Dementia Research Institute (UK DRI). Our renowned co-founders Prof Chris Shaw, Dr Youn Bok Lee and Dr Do Young Lee bring a wealth of deep scientific, clinical and neuroscience expertise to our team.
BioArctic is a Swedish research intensive biopharma company aimed at developing new treatments that address the causes of disorders that affect the Central Nervous System. These types of treatments are commonly referred to as “disease modifiers”. They affect the underlying disease pathology and can hopefully stop or significantly delay disease progression. This is a large paradigm shift from today’s symptom-oriented therapies.
BioArctic’s proprietary technology platform, dedicated personnel, collaborations with leading academic research groups and the global pharma industry have made it possible to develop innovative treatments based on antibodies (immunotherapy) for neurodegenerative disorders.
Calliditas Therapeutics is a specialty pharmaceutical company focused on developing high value medical products for patients with significant unmet medical needs in niche indications, where the company can partially or completely participate in the commercialization. Initial focus is in renal and hepatic indications.
Cardior Pharmaceuticals is a clinical-stage, privately held German biopharmaceutical company pioneering the development of curative and preventive heart failure therapeutics based on noncoding RNAs (ncRNAs).
Cardior’s therapeutic approach is using distinctive ncRNA signatures driving the molecular reprogramming that causes maladaptive remodeling and heart failure. Drug candidates developed by Cardior represent first-in-class ncRNA therapeutics and diagnostics for patients with myocardial infarction and various forms of heart failure.
Founded in 2016 based on the work of cardiologist Prof. Dr. Dr. Thomas Thum of Hannover Medical School, the Company is funded by a consortium of leading investors: LSP, BioMedPartners, Boehringer Ingelheim Venture Fund (BIVF), Bristol-Myers Squibb (BMS) and High-Tech Gründerfonds (HTGF).
Egle Therapeutics (FR)
Established in early 2020, as a spin-out of Institut Curie by Luc Boblet, serial biotech entrepreneur, and Dr Eliane Piaggio PhD, Director of the Translational Immunotherapy Team at Institut Curie, Egle Therapeutics is developing first-in-class immunotherapies targeting suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases.
Egle’s scientific foundations benefits from decades of breakthrough academic research leading to unprecedented computational based IL-2 modified variants and a unique translational-based target discovery platform unveiling novel therapeutic Treg targets.
The key element of Egle’s core approach leverages of unifying therapeutic potentials of antibody specific targeting combined with the selective mechanism of action of modified cytokine for arming or disarming the most immunosuppressive Tregs to restore the immune response.
Egle deploys its first-in-class technology platforms to building a furnished drug pipeline of novel immunotherapies against Tregs with tremendous potential in the oncology and auto-immunity fields.
eTheRNA is an mRNA technology discovery and development company with a full platform of integrated capabilities including: mRNA construct design and optimization; proprietary lipid nanoparticle (LNP) formulations which have demonstrated organ-specific distribution preclinically; process development and manufacturing capabilities for mRNA drug substance (gram GMP scale); and proprietary LNP / final product formulation technologies, including a lyophilized thermostable formulation in advanced development. With a focus on immune modulation and T Cell stimulation, eTheRNA is pursuing internal development programs to validate its core technologies and enable strategic partnerships in a range of geographic markets and therapeutic areas. eTheRNA is backed by a global syndicate of leading investors and is headquartered in Belgium with offices in New York and Hong Kong. To learn more, visit www.etherna.be.
We are a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system in order to tackle cancer and inflammation. Since our founding in 2007, our goal has been to develop a diverse and unique pipeline rooted in high quality science and innovation. Faron is focused on mastering immune modulation by harnessing endothelial receptors to control and mediate immune responses. We are disrupting the current treatment landscape with a novel pipeline of immune modulation based proprietary drug candidates with numerous applications tackling major unmet needs including immuno-oncology, and organ protection and regenerative medicine. Faron works today with tomorrow’s breakthroughs. Our main focus is on our core scientific and clinical development expertise and advancing our broad pipeline of novel programs including Bexmarilimab in oncology, Traumakine in organ protection and Haematokine in regenerative medicine. Working closely with our network of trusted strategic collaborators we are able to give our pipeline the greatest chances of success with a focus on improving the lives of patients suffering from devastating diseases.
Flamingo Therapeutics (BE)
At Flamingo, we understand drug development – and more importantly – we understand RNA therapeutic drug development. We know that robust and novel backbone chemistry is paramount when developing any RNA therapeutic, especially for difficult to treat cancers, where many modalities have failed to succeed. Our company was built upon our deep experience and know-how in this space and we are well-positioned to advance candidates against targets considered “undruggable” by conventional chemistries.
Flamingo has the most advanced antisense RNA-targeting oncology portfolio with three clinical programs targeting undruggable transcription factors and splice variants. We also have a proprietary discovery engine, FLAME™ (Flamingo LncRNA Antisense Mining Engine), that addresses lncRNAs, a large and untapped class of disease-causing targets within the “dark matter” of the human genome. The Company was founded in 2020 based on pioneering work in the field of lncRNAs in oncology with our academic partners at VIB, KU Leuven, Ghent University and The University of Michigan. Flamingo has a strategic partnership with Ionis Pharmaceuticals and is supported by well-known biotechnology investors Kurma Partners and PMV. The company is headquartered in Belgium with additional operations in San Diego, CA
FoRx Therapeutics (CH)
FoRx Therapeutics is a recently incorporated privately-held company based in Basel, Switzerland. It is backed by a syndicate of investors that include the Novartis Venture Fund, Pfizer Ventures, M Ventures, Omega Funds and LSP Venture Capital. FoRx Therapeutics focuses on drugging key molecular targets involved in DNA Replication Stress, as a new approach towards the development of targeted anticancer drugs.
ImCheck Therapeutics (FR)
ImCheck Therapeutics is a clinical stage biotech company offering unique opportunities for immune modulation by targeting a superfamily of new targets: Butyrophilins (BTNs).
The superfamily of BTNs consists of 14 genes offering separate and distinct mechanisms of action that have not previously been explored in immuno-oncology or autoimmunity including Vγ9Vδ2 T-cells, NK-cells, αβ T-Cells and myeloid cells.
Imcheck Therapeutics is advancing a diverse pipeline of programs against different targets within the BTN family for use in monotherapy or combination with existing drugs to the benefit patients suffering from cancer or autoimmune disorders.
Imcyse develops active targeted immunotherapies to treat and prevent severe chronic diseases caused by disruptions of the immune system. Imcyse’s unique active immunotherapy technology platform, based on the administration of Imotopes™, allows it to locally target immune cells involved in the destruction of the diseased organ. Imcyse has completed its first clinical trial in type 1 diabetes in 7 European countries. Projects which address multiple sclerosis and rheumatoid arthritis, are at preclinical and proof-of-concept research stages, respectively.
Learn more here
Innovative Molecules (DE)
Innovative Molecules is a drug development company focused on developing next-generation treatments for Herpes simplex virus infection and diseases.
The company`s focus is on the development of IM-250, a potent inhibitor of Herpes Simplex Virus type 1 (HSV-1) and type 2 (HSV-2) replication. The compound targets the helicase-primase enzyme complex of the virus. In preclinical studies IM-250 demonstrated an impact on the viral reservoir in nerve cells and may become a game-changer for the treatment of HSV-related diseases due to its potential to alter the natural course of the chronically-persistent disease. Of note, the compound not only reduces the duration of symptoms and time to healing, but also reduces the frequency of recurrences and the degree of viral shedding.
Innovative Molecules closed a €20 million Series A equity financing round led by LSP (Life Sciences Partners) in June 2021.The company will use the funds to advance IM-250 from the current late preclinical stage to a Phase 2 proof-of-concept study.
iStar Medical (BE)
iSTAR Medical, founded in 2011 and headquartered in Wavre, Belgium, is a clinical-stage, medical technology company focused on the development of novel ophthalmic implants for patients with glaucoma. Glaucoma is the second leading cause of adult blindness globally, affecting more than 90 million people. Micro-invasive glaucoma surgery (MIGS) is the most promising and fastest-growing therapeutic option in the treatment of glaucoma.
iSTAR’s lead product, MINIject ™, has been designed to be a best-in-class MIGS device. Data from its first-in-human STAR-I trial confirms that it is safe and highly effective in achieving significant IOP reduction, as well as easing medication burden in glaucoma patients. Several additional studies are in progress to support iSTAR’s market entry plans into Europe and the United States.
iSTAR has raised €55 million to-date.
Kuros Biosciences is a leader in next generation synthetic bone graft technologies for targeted and controlled bone healing. Kuros’s bone graft substitute, MagnetOs, is commercialized in the US and UK for use in posterolateral spinal fusions. Kuros’s lead product in development, Fibrin PTH, a drug-biologic combination for spinal interbody fusion, has entered a phase 2 clinical trial in the U.S. Kuros is located in Schlieren (Zurich), Switzerland, Bilthoven, The Netherlands and Burlington (MA), U.S.A. The Company is listed according to the International Financial Reporting Standard on the SIX Swiss Exchange under the symbol KURN.
Lumeon transforms fragmented, manual processes into connected, personalized digital care experiences. It helps you ensure the delivery of the right care, for every patient, every time.
At the heart of Lumeon’s platform is our powerful, programmable orchestration engine, allowing you to launch precision care journeys in record time.
The best care is delivered by care teams that collaborate across the care continuum, but information silos and technology fragmentation lead to repetition, burnout and risk.
Lumeon enables care teams to work at the top of their licenses by automating repetitive documentation and personalizing the care journey.
The EHR has delivered transformative data to health systems but operationalizing that data to enable the transformation needed post-COVID requires a new set of tools.
Lumeon acts as an agility layer to supplement limited orchestration capabilities in the EHR and amplify your investment to reduce costs and increase revenues for sustainable care.
Muna Therapeutics discovers and develops therapies that slow or stop devastating neurodegenerative diseases including Alzheimer’s, Frontotemporal Dementia and Parkinson’s. These disorders impact memory, movement, language, behavior and personality resulting in disability and death of millions of patients around the globe.
We focus our groundbreaking science on identifying new medicines to preserve cognition and other brain functions and enhance resilience to neurodegenerative diseases.
Our name reflects this focus: Muna means ‘to remember’ in Old Norse.
Neurent Medical (IE)
Neurent Medical, founded in 2017, is pioneering innovative treatments for chronic inflammatory sino-nasal diseases by targeting and safely disrupting hyperactive parasympathetic nerves that drive underlying inflammation. The Galway, Ireland-based company has developed NEUROMARK™ Rhinitis Neurolysis Therapy™, an innovative in-office treatment option for chronic rhinitis. Neurent Medical closed a €9.3m Series A in 2018, led by Fountain Healthcare Partners, and a €21m Series B in 2020, led by LSP. Neurent Medical is actively enrolling patients into its pivotal clinical trial of their NEUROMARK™ technology and preparing for its US commercialisation later in 2021.
New Amsterdam Pharma (NL)
At NewAmsterdam Pharma, we are passionate about providing transformational therapies for patients suffering from an array of conditions where aberrant cholesterol metabolism still underlies significant morbidity and mortality. We are developing safe, convenient, oral medications for metabolic diseases to help transform the treatment paradigm for these patients.
Our lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP) which has been clinically shown to significantly reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). CETP functions to transport cholesterol from ‘good’ HDL to ‘bad’ LDL. Obicetrapib works by blocking this transfer, thus substantially lowering LDL while simultaneously increasing HDL. We believe by transforming the ratio of ‘good’ versus ‘bad’ cholesterol in the body, obicetrapib holds transformative treatment potential for patients.
Nobi is a smart lamp. Its motto? Happiest at home. Its mission? Create technology that helps elderly people to live their lives in happiness, dignity and independence. At home, in a serviced flat or a nursing home – wherever people need care, Nobi ads quality and efficiency. Nobi is a guardian angel, with fall prevention and fall detection, but also with fire and burglar alarms or continuous health monitoring. Nobi was launched in 2018 in Belgium by a team of seasoned smart home and elderly care entrepreneurs. Today, the company is expanding in the EU and has opened its first office in the US.
Nouscom is an oncology company developing next-generation immunotherapies. Nouscom’s proprietary technology harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators. Nouscom raised 54M EUR to date, and is backed by a strong syndicate of international investors: 5AM, Abingworth, LSP, and Versant Ventures.
Despite technological advances, ablation treatment for the millions of patients suffering with AFib is only successful in around half of patients. OneProjects are developing VERAFEYE, a novel endovascular catheter system to increase the efficacy and safety of cardiac ablations. VERAFEYE, utilizing advanced imaging and analytics in conjunction with its innovative catheter-based sensor system, is a connected technology generating unprecedented 4D data during the cardiac ablation procedure. By providing the physician with real-time high resolution anatomical maps of the cardiac structures and beyond, VERAFEYE will aid in therapy planning (cardiac wall thickness/morphology etc.) and also include imaging of ablation lesions as they are created in the heart muscle to increase the efficacy as well as the safety of catheter ablation.
The company vision is to provide data of unparalleled data to physicians to make effective treatment accessible to the growing number of patients worldwide while reducing cost to the healthcare system.
OneProjects offices are located in Dublin, Ireland and Munich, Germany.
ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARCIM) or external (ARCEX) systems, is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. ONWARD has received three Breakthrough Device Designations from the FDA encompassing both ARCIM and ARCEX. The company’s first FDA pivotal trial, called Up-LIFT, completed enrollment in December 2021 with 65 subjects worldwide. ONWARD’s technology is protected by over 310 issued or pending patents globally.
ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands. It maintains a significant team in Lausanne, Switzerland and has a growing U.S. presence in Boston, Massachusetts, USA. For additional information about the company, please visit ONWD.com. To access our 2022 Financial Calendar, please visit IR.ONWD.com.
Orphazyme was founded in Denmark in 2009 based on a scientific discovery about the role of heat shock proteins (HSPs), which was described in a well-cited article published in the journal Nature. One of the lead authors of that paper, Thomas Kirkegaard Jensen, is a founder of our company and our Chief Scientific Officer.
Today, we have translated that scientific discovery into a late-stage clinical development program. We are working to obtain regulatory approvals that will allow us to bring a novel treatment to patients, applying our knowledge of heat shock proteins (HSPs) for the benefit of people living with rare neurodegenerative diseases.
Oryzon Genomics (ESP)
A public clinical-stage biopharma developing epigenetics for CNS disorders and Oncology. +50 highly-qualified professionals located in Barcelona, Boston, NYC and San Diego. Listed in Spain aiming NASDAQ-listing.
Two uncorrelated Phase-II compounds: Iadademstat, best-in-class LSD1-inhibitor, (AML and solid-tumors). PoC with strong clinical activity in a Phase-II in unfit-AML patients and encouraging signals in 2L-ED-SCLC. Currently launching Phase-II trials in these with registrational potential.
In CNS, Vafidemstat, a safe LSD1-inhibitor. Positive results reducing aggression in a basket trial with psychiatric patients. Two Phase-IIb programs in SCZ and Borderline-personality recruiting now. Launching a personalized-medicine program: a Phase-II trial in Kabuki-syndrome with registrational potential.
Perfuze is an interventional neurovascular company focused on Acute Ischemic Stroke. Perfuze has developed super-bore diameter aspiration technology that has the capability to navigate the complex neurovascular anatomy. Perfuze’ pipeline of products are designed to facilitate fast, complete clot removal from the brain during acute ischemic stroke. Perfuze has CE Mark approval for its first device, Millipede 088 and has successfully treated its first cohort of patients.
Pharvaris is a clinical-stage company focused on bringing oral bradykinin B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.
PHA121, Pharvaris’ lead drug candidate, is a novel, potent small-molecule bradykinin B2 receptor antagonist. PHA121 is the only oral B2-receptor antagonist in clinical development, currently under Phase 1 clinical study.
Pharvaris was founded in October 2015 by executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE.
Pulsify Medical (BE)
World class technology
Pulsify Medical is a spin-off from both imec as well as the Catholic University Leuven (Medical Imaging Center). Both partners contribute critical, state-of-the-art technology and research support.
The combined technologies of imec and KU Leuven enable a breakthrough in non-invasive, continuous cardiac monitoring. The current solutions in the market are often invasive, using a type of catheter to enter the patient’s body. This is only an option in an Intensive Care Unit (ICU), but not elsewhere. The other alternative is to use the classical ultrasound probe. This is a handheld device, that can only be used for a very short period of time. These cannot monitor the cardiac performance on an ongoing basis.
Pulsify’s patch enables monitoring of the cardiac performance continuously, a comforting thought for both patient and physician.
Sequana Medical (CH)
Sequana Medical NV is a commercial stage medical device company developing the alfapump® platform for the treatment of fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. Fluid overload is a fast growing complication of advanced liver disease driven by NASH (non-alcoholic steatohepatitis) related cirrhosis and a common complication in heart failure with diuretic resistance being widespread in both of these indications.
Both indications leverage Sequana Medical’s alfapump, a unique, fully implanted wireless device that automatically pumps fluid from the abdomen into the bladder, where it is naturally eliminated through urination. The alfapump has been granted FDA breakthrough device designation for recurrent and refractory ascites due to liver cirrhosis with a pivotal study in the U.S. and Canada (POSEIDON) underway, and is approved in Europe for refractory ascites due to liver cirrhosis and malignant ascites. Over 800 alfapump systems have been implanted to date. The alfapump DSR® (Direct Sodium Removal) builds on this experience and is in development as a potential chronic therapy for fluid overload in heart failure. Clinical proof-of-concept was achieved and strong interim results have been published from an ongoing repeated dose alfapump DSR study (RED DESERT) in diuretic-resistant heart failure patients.
Sequana Medical is headquartered in Ghent, Belgium. For further information, please visit [www.sequanamedical.com](http://www.sequanamedical.com).
SNIPR Biome (DK)
SNIPR BIOME: We are the CRISPR microbiome company. Precision killing of bacteria has the impact to revolutionize the management of untreatable and difficult-to-treat infections as well as complex diseases directly impacted by the human microbiota.
Our mission is to develop CRISPR-based medicines that give hope for effective and safe treatment of difficult-to-treat diseases in the future.
T-knife Therapeutics (DE)
T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a modality that holds the potential to generate transformative responses in patients with solid tumors. The Company’s unique approach leverages its proprietary HuTCR mouse platform, a next-generation T cell receptor and epitope discovery engine that produces fully human, tumor-specific TCRs, naturally selected in vivo for optimal affinity and high specificity.
T-knife is advancing a portfolio of TCR-T product candidates against targets with high unmet medical need, including cancer testis antigens, oncoviral antigens and commonly shared tumor-driving neoantigens. T-knife was founded by leading T-cell and immunology experts using technology developed at the Max Delbruck Center for Molecular Medicine together with Charité – Universitätsmedizin Berlin. For additional information, please visit the company’s website at www.t-knife.com.
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.
Venari Medical (IE)
Venari Medical is developing a novel medical device for the office-based treatment of chronic venous disease, a condition that affects up to one in three people worldwide.
We are developing a less-invasive, effective, pain-free and faster minimally invasive endovenous medical device treatment for all chronic venous disease patients. Our device is the world ’s first effective non-thermal medical device to cure varicose veins and venous ulcers, collectively known as chronic venous disease*. Our device uses the body’s natural healing response to cure symptoms allowing all chronic venous disease sufferers receive treatment for the first time.
“We exist to create innovative products that give people more time to enjoy life. We do things differently, but only when that difference is meaningful. Our goal is to be a company people know they can rely on, a friend that’s on their side.”
ViCentra is an innovative medical device company based in Utrecht, The Netherlands, with a ground-breaking product for the management of Type 1 diabetes. Kaleido, the world’s smallest and lightest insulin pump system is designed to help people with diabetes live life on their own terms.
VICO Therapeutics (NL)
VICO was founded in Q4 2019 by the highly experienced entrepreneurs Luc Dochez and Josh Mandel-Brehm and seasoned scientists Dr. Judith van Deutekom and Dr. Gail Mandel with strong academic reputations and vast industry experience.
Become a recognized leader bringing innovative oligonucleotide based RNA modulating therapeutics to patients suffering from rare CNS disorders.
We foster positive and collaborative relationships with all stakeholders, including patients, academics, physicians and our employees, essential for the development of new therapies for rare CNS disorders.
It is our mission to advance these therapies and our team is committed to realize the full potential of our pipeline and technologies to the benefit of patients.
Our programs are driven by a highly competent and experienced team consisting of molecular biologists, chemists and drug development experts with over a decade of experience in bringing novel therapies into the clinic and to the market.
Vivasure Medical (IE)
Vivasure Medical Limited (“Vivasure”) is a medical device company developing innovative solutions for unmet clinical needs in cardiology, interventional radiology and vascular surgery. Vivasure’s patented platform technology is designed to close large holes in blood vessels, such as those made to facilitate percutaneous cardiac valve repairs or replacements. Its lead product, PerQseal®, is CE Mark approved and is currently in the early stages of commercialisation in the EU. Vivasure operates a fully integrated, ISO 13485:2016 certified R&D and manufacturing facility. The company is staffed by a widely experienced team of medical device professionals.
Vivoryon Therapeutics (DE)
At Vivoryon, we are passionate about creating small molecule medicines to improve the lives of all those who are affected by severe diseases. We build on our in-depth expertise in understanding post-translational modifications and pathologic pathways to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. Our lead candidate, varoglutamstat is currently in Phase 2 clinical studies to treat Alzheimer’s disease.
WhiteSwell is a science-driven company dedicated to improving treatment of acute decompensated heart failure (ADHF), a primary cause of repeat hospitalization and emergency room visits. The quest to address this significant clinical need led the WhiteSwell team to explore the therapeutic potential of the lymphatic system. WhiteSwell’s solution is uniquely designed to facilitate removal of fluid from both the interstitial and intravascular compartments.
Xeltis ETR technology has been tested in various cardiovascular feasibility clinical trials (Fontan, Atrial patch and Pulmonary valve). Xeltis closed a Series B financing and an extension based on these first promising clinical results. In 2017 the company closed a round of 45 M to further expand applications in the cardiovascular space.